bioRxivBiochemistryPreprint
A Rationally Designed Antimicrobial Peptide from Structural and Functional Insight of Clostridium difficile Translation Initiation Factor 1
E. Alanis, F. Aguilar, N. Banaei, F. B. Dean, M. Alanis, J. M. Bullard, Y. Zhang
Abstract
A significant increase of hospital-acquired bacterial infections during the COVID-19 pandemic has become an urgent medical problem. Clostridioides difficile is an urgent antibiotic-resistant bacterial pathogen and a leading causative agent of nosocomial infections. The increasing recurrence of C. difficile infection and antibiotic resistance in C. difficile has led to an unmet need for discovery of new compounds distinctly different from present antimicrobials, while antimicrobial peptides as promising alternatives to conventional antibiotics have attracted growing interest recently. Protein synthesis is an essential metabolic process in all bacteria and a validated antibiotic target. Initiation factor 1 from C. difficile (Cd-IF1) is the smallest of the three initiation factors that acts to establish the 30S initiation complex to initiate translation during protein biosynthesis. Here we report the solution NMR structure of Cd-IF1 which adopts a typical {beta}-barrel fold and consists of a five-stranded {beta}-sheet and one short -helix arranged in the sequential order {beta}1-{beta}2-{beta}3-1-{beta}4-{beta}5. The interaction of Cd-IF1 with the 30S ribosomal subunit was studied by NMR titration for the construction of a structural model of Cd-IF1 binding with the 30S subunit. The short -helix in IF1 was found to be critical for IF1 ribosomal binding. A peptide derived from this -helix was tested and displayed a high ability to inhibit the growth of C. difficile and other bacterial strains. These results provide a clue for rational design of new antimicrobials.
- organism: C. elegans
- assay: protein structure
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- De novo design of potent inhibitors of Clostridioides difficile toxin B
Robert J. Ragotte, Huazhu Liang, … David A. Baker·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 22, 2025
- A unique class of Zn2+-binding PBPs underlies cephalosporin resistance and sporogenesis in Clostridioides difficile
M. D. Sacco, S. Wang, … Y. Chen·bioRxiv·Jan 4, 2022
- Basis of narrow-spectrum activity of fidaxomicin on gut pathogen Clostridioides difficile
X. Cao, H. Boyaci, … E. A. Campbell·bioRxiv·Jan 17, 2022
- In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
C. Dureja, J. T. Rutherford, … J. G. Hurdle·bioRxiv·Sep 22, 2023
- Antiviral Library Screening Leads to Discovery of Novel and Potent Anticlostridial Compounds
Brice Jasarino Stolz, Mohamed N. Seleem·PLoS ONEPeer-reviewed·Dec 13, 2024
- Structural basis for the context-specific action of classic peptidyl transferase inhibitors.
Egor A. Syroegin, Laurin Flemmich, … Yury S. Polikanov·Nature Structural & Molecular BiologyPeer-reviewed·Feb 1, 2022